Eli Lilly's Dominance in Weight Loss Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: Fool
- Market Leadership: Eli Lilly's weight loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, demonstrating its strong performance in the rapidly growing weight loss market and solidifying the company's leadership position.
- Emerging Competitors: Regeneron's olatorepatide achieved a 19% mean weight loss in a phase 3 study conducted in China, closely rivaling Zepbound's 20.2%, indicating its potential as a serious competitor in the weight loss drug market that could challenge Eli Lilly.
- New Drug Development Progress: Eli Lilly's oral GLP-1 drug forglipron is expected to launch in the second quarter, and with promising phase 3 results in diabetes and obesity, it could capture a leading share of the oral weight loss market, further enhancing the company's competitive edge.
- Technological Investment and Future Outlook: Eli Lilly is heavily investing in artificial intelligence to accelerate the drug discovery process, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its continued dominance in the weight loss market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 977.250
Low
950.00
Averages
1192
High
1500
Current: 977.250
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Denies AstraZeneca Acquisition Talks
- Acquisition Rumor Denial: Abivax has denied media reports claiming that AstraZeneca was in talks to acquire the company, despite the report stating that AstraZeneca had exclusive access to Abivax's data since February and had until March 23 to formalize an offer.
- Stock Price Fluctuation: Following the report, Abivax's shares surged by as much as 15%, but ultimately closed about 4% higher, indicating a cautious market reaction to the acquisition rumors.
- Potential Acquisition Interest: Analysts suggest that Abivax's immunology and inflammation drug obefazimod could attract large pharmaceutical companies for acquisition, especially after its strong performance in last year's late-stage trials, enhancing its strategic value.
- Competitor Attention: In addition to AstraZeneca, Eli Lilly has also been rumored to be in talks with Abivax regarding a potential acquisition, although both companies have declined to comment, reflecting strong market interest in Abivax.
See More
Eli Lilly's Dominance in Weight Loss Market
- Market Leadership: Eli Lilly's weight loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, demonstrating its strong performance in the rapidly growing weight loss market and solidifying the company's leadership position.
- Emerging Competitors: Regeneron's olatorepatide achieved a 19% mean weight loss in a phase 3 study conducted in China, closely rivaling Zepbound's 20.2%, indicating its potential as a serious competitor in the weight loss drug market that could challenge Eli Lilly.
- New Drug Development Progress: Eli Lilly's oral GLP-1 drug forglipron is expected to launch in the second quarter, and with promising phase 3 results in diabetes and obesity, it could capture a leading share of the oral weight loss market, further enhancing the company's competitive edge.
- Technological Investment and Future Outlook: Eli Lilly is heavily investing in artificial intelligence to accelerate the drug discovery process, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its continued dominance in the weight loss market.
See More
Eli Lilly's Leadership in Weight Loss Market
- Market Leadership: Eli Lilly's weight-loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, showcasing its strong competitive position in the rapidly growing weight loss market.
- Competitive Threats: Despite Eli Lilly's dominance, competitors like Regeneron, Roche, and Novo Nordisk have shown promising results in China, achieving mean weight losses of 19%, 22.5%, and 19.7% respectively, which could pose future challenges to Zepbound.
- New Product Progress: Eli Lilly's oral GLP-1 drug, forglipron, is expected to launch in Q2, and with strong phase 3 results in diabetes and obesity, it is poised to capture a leading share of the oral weight-loss market, further solidifying its market position.
- Technology Investment: Eli Lilly is heavily investing in artificial intelligence to accelerate drug discovery, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its sustained advantage in the weight loss market.
See More
Kroger Launches New Medication to Boost Market Performance
- New Medication Launch: Kroger has introduced the Zepbound KwikPen at participating pharmacies, a multi-dose self-administration option aimed at meeting high demand for weight management medications, thereby enhancing the company's competitive edge in the healthcare sector.
- Stock Performance: Kroger shares are priced at $75.09, trading 7.2% above the 20-day simple moving average, indicating strong short-term momentum, although overall performance lags behind the consumer discretionary sector's average.
- Financial Outlook: Kroger is set to release its financial report on June 22, 2026, with analysts optimistic about earnings per share rising from $1.49 to $1.59 and revenue expectations at $45.39 billion, showcasing the company's growth potential.
- Analyst Ratings: Kroger stock holds a Buy rating with an average price target of $74.07, with Evercore ISI raising its target to $83.00, reflecting market confidence in the company's future performance.
See More
Kroger Introduces Zepbound® KwikPen in Retail Pharmacies, Enhancing Access and Cost Savings for Self-Paying Patients
Expansion of Services: KROGER BRINGS ZEPBOUND® KWIKPEN to retail pharmacy, enhancing access for self-pay patients.
Focus on Savings: The initiative aims to provide savings opportunities for patients who pay out-of-pocket for their medications.
See More
S&P 500 Healthcare Holdings Growth Factor Grades Analysis
- Healthcare Growth Ratings: The S&P 500 healthcare sector has faced turbulence, with Eli Lilly (LLY) leading with an A grade, indicating strong growth potential that may attract investor interest.
- Sector Rotation Trends: Amid escalating geopolitical tensions, investors are shifting towards defensive stocks, resulting in technical deterioration for healthcare stocks, which impacts overall market sentiment.
- Low Growth Rated Companies: Companies like Thermo Fisher (TMO), Abbott (ABT), and Merck (MRK) received D- grades, indicating they face growth challenges in the current market environment, potentially affecting their stock performance.
- Rating Impact Analysis: Growth factor grades serve as a crucial metric for assessing a company's expansion potential, with Eli Lilly's A rating starkly contrasting with other lower-rated companies, likely prompting investors to reassess their portfolio allocations.
See More
Abivax Denies AstraZeneca Acquisition Talks
- Acquisition Rumor Denial: Abivax has denied media reports claiming that AstraZeneca was in talks to acquire the company, despite the report stating that AstraZeneca had exclusive access to Abivax's data since February and had until March 23 to formalize an offer.
- Stock Price Fluctuation: Following the report, Abivax's shares surged by as much as 15%, but ultimately closed about 4% higher, indicating a cautious market reaction to the acquisition rumors.
- Potential Acquisition Interest: Analysts suggest that Abivax's immunology and inflammation drug obefazimod could attract large pharmaceutical companies for acquisition, especially after its strong performance in last year's late-stage trials, enhancing its strategic value.
- Competitor Attention: In addition to AstraZeneca, Eli Lilly has also been rumored to be in talks with Abivax regarding a potential acquisition, although both companies have declined to comment, reflecting strong market interest in Abivax.
See More
Eli Lilly's Dominance in Weight Loss Market
- Market Leadership: Eli Lilly's weight loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, demonstrating its strong performance in the rapidly growing weight loss market and solidifying the company's leadership position.
- Emerging Competitors: Regeneron's olatorepatide achieved a 19% mean weight loss in a phase 3 study conducted in China, closely rivaling Zepbound's 20.2%, indicating its potential as a serious competitor in the weight loss drug market that could challenge Eli Lilly.
- New Drug Development Progress: Eli Lilly's oral GLP-1 drug forglipron is expected to launch in the second quarter, and with promising phase 3 results in diabetes and obesity, it could capture a leading share of the oral weight loss market, further enhancing the company's competitive edge.
- Technological Investment and Future Outlook: Eli Lilly is heavily investing in artificial intelligence to accelerate the drug discovery process, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its continued dominance in the weight loss market.
See More
Eli Lilly's Leadership in Weight Loss Market
- Market Leadership: Eli Lilly's weight-loss drug Zepbound became the best-selling drug globally in 2025, generating $65.2 billion in revenue, a 45% year-over-year increase, showcasing its strong competitive position in the rapidly growing weight loss market.
- Competitive Threats: Despite Eli Lilly's dominance, competitors like Regeneron, Roche, and Novo Nordisk have shown promising results in China, achieving mean weight losses of 19%, 22.5%, and 19.7% respectively, which could pose future challenges to Zepbound.
- New Product Progress: Eli Lilly's oral GLP-1 drug, forglipron, is expected to launch in Q2, and with strong phase 3 results in diabetes and obesity, it is poised to capture a leading share of the oral weight-loss market, further solidifying its market position.
- Technology Investment: Eli Lilly is heavily investing in artificial intelligence to accelerate drug discovery, a strategy that not only enhances R&D efficiency but could also yield significant financial returns in the future, ensuring its sustained advantage in the weight loss market.
See More
Kroger Launches New Medication to Boost Market Performance
- New Medication Launch: Kroger has introduced the Zepbound KwikPen at participating pharmacies, a multi-dose self-administration option aimed at meeting high demand for weight management medications, thereby enhancing the company's competitive edge in the healthcare sector.
- Stock Performance: Kroger shares are priced at $75.09, trading 7.2% above the 20-day simple moving average, indicating strong short-term momentum, although overall performance lags behind the consumer discretionary sector's average.
- Financial Outlook: Kroger is set to release its financial report on June 22, 2026, with analysts optimistic about earnings per share rising from $1.49 to $1.59 and revenue expectations at $45.39 billion, showcasing the company's growth potential.
- Analyst Ratings: Kroger stock holds a Buy rating with an average price target of $74.07, with Evercore ISI raising its target to $83.00, reflecting market confidence in the company's future performance.
See More
Kroger Introduces Zepbound® KwikPen in Retail Pharmacies, Enhancing Access and Cost Savings for Self-Paying Patients
Expansion of Services: KROGER BRINGS ZEPBOUND® KWIKPEN to retail pharmacy, enhancing access for self-pay patients.
Focus on Savings: The initiative aims to provide savings opportunities for patients who pay out-of-pocket for their medications.
See More
S&P 500 Healthcare Holdings Growth Factor Grades Analysis
- Healthcare Growth Ratings: The S&P 500 healthcare sector has faced turbulence, with Eli Lilly (LLY) leading with an A grade, indicating strong growth potential that may attract investor interest.
- Sector Rotation Trends: Amid escalating geopolitical tensions, investors are shifting towards defensive stocks, resulting in technical deterioration for healthcare stocks, which impacts overall market sentiment.
- Low Growth Rated Companies: Companies like Thermo Fisher (TMO), Abbott (ABT), and Merck (MRK) received D- grades, indicating they face growth challenges in the current market environment, potentially affecting their stock performance.
- Rating Impact Analysis: Growth factor grades serve as a crucial metric for assessing a company's expansion potential, with Eli Lilly's A rating starkly contrasting with other lower-rated companies, likely prompting investors to reassess their portfolio allocations.
See More
